JP2019011344A5 - - Google Patents

Download PDF

Info

Publication number
JP2019011344A5
JP2019011344A5 JP2018176400A JP2018176400A JP2019011344A5 JP 2019011344 A5 JP2019011344 A5 JP 2019011344A5 JP 2018176400 A JP2018176400 A JP 2018176400A JP 2018176400 A JP2018176400 A JP 2018176400A JP 2019011344 A5 JP2019011344 A5 JP 2019011344A5
Authority
JP
Japan
Prior art keywords
virus
influenza
influenza virus
sia
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018176400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019011344A (ja
JP7260270B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019011344A publication Critical patent/JP2019011344A/ja
Publication of JP2019011344A5 publication Critical patent/JP2019011344A5/ja
Application granted granted Critical
Publication of JP7260270B2 publication Critical patent/JP7260270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018176400A 2006-09-11 2018-09-20 卵を使用しないインフルエンザウイルスワクチンの作製 Active JP7260270B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84372006P 2006-09-11 2006-09-11
US60/843,720 2006-09-11
US93627907P 2007-06-18 2007-06-18
US60/936,279 2007-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016021859A Division JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020028399A Division JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製

Publications (3)

Publication Number Publication Date
JP2019011344A JP2019011344A (ja) 2019-01-24
JP2019011344A5 true JP2019011344A5 (cg-RX-API-DMAC7.html) 2019-07-25
JP7260270B2 JP7260270B2 (ja) 2023-04-18

Family

ID=39184185

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2009527227A Active JP5954921B2 (ja) 2006-09-11 2007-09-11 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016021859A Withdrawn JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製
JP2017038957A Pending JP2017101073A (ja) 2006-09-11 2017-03-02 卵を使用しないインフルエンザウイルスワクチンの作製
JP2018176400A Active JP7260270B2 (ja) 2006-09-11 2018-09-20 卵を使用しないインフルエンザウイルスワクチンの作製
JP2020028399A Withdrawn JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製
JP2021215388A Active JP7427648B2 (ja) 2006-09-11 2021-12-29 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023074617A Pending JP2023093728A (ja) 2006-09-11 2023-04-28 卵を使用しないインフルエンザウイルスワクチンの作製

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009527227A Active JP5954921B2 (ja) 2006-09-11 2007-09-11 卵を使用しないインフルエンザウイルスワクチンの作製
JP2016021859A Withdrawn JP2016074747A (ja) 2006-09-11 2016-02-08 卵を使用しないインフルエンザウイルスワクチンの作製
JP2017038957A Pending JP2017101073A (ja) 2006-09-11 2017-03-02 卵を使用しないインフルエンザウイルスワクチンの作製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020028399A Withdrawn JP2020073616A (ja) 2006-09-11 2020-02-21 卵を使用しないインフルエンザウイルスワクチンの作製
JP2021215388A Active JP7427648B2 (ja) 2006-09-11 2021-12-29 卵を使用しないインフルエンザウイルスワクチンの作製
JP2023074617A Pending JP2023093728A (ja) 2006-09-11 2023-04-28 卵を使用しないインフルエンザウイルスワクチンの作製

Country Status (12)

Country Link
US (3) US20100010199A1 (cg-RX-API-DMAC7.html)
EP (4) EP2497495B3 (cg-RX-API-DMAC7.html)
JP (7) JP5954921B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090057015A (cg-RX-API-DMAC7.html)
AU (1) AU2007297178B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716536A2 (cg-RX-API-DMAC7.html)
CA (2) CA3016948A1 (cg-RX-API-DMAC7.html)
EA (1) EA200970271A1 (cg-RX-API-DMAC7.html)
ES (3) ES2694805T7 (cg-RX-API-DMAC7.html)
MX (1) MX2009002408A (cg-RX-API-DMAC7.html)
NZ (1) NZ575271A (cg-RX-API-DMAC7.html)
WO (1) WO2008032219A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
EP2121011B1 (en) * 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP2361304A2 (en) * 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
JP2012517416A (ja) * 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
KR101825697B1 (ko) 2009-02-10 2018-02-05 노파르티스 아게 감소된 양의 스쿠알렌을 포함하는 인플루엔자 백신
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CN102548577A (zh) * 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
CA2800182A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP5823379B2 (ja) 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
JP5845180B2 (ja) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CN101804203A (zh) * 2010-05-10 2010-08-18 洛阳普莱柯生物工程有限公司 一种大规模生产伪狂犬病毒疫苗的方法
WO2012023044A1 (en) * 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012033236A1 (ko) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
CA2828192A1 (en) 2011-02-25 2012-08-30 Novartis Ag Exogenous internal positive control
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CN102586195B (zh) * 2011-12-01 2013-09-04 哈药集团生物疫苗有限公司 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法
US20140335507A1 (en) 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
KR102453351B1 (ko) * 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110237246B (zh) * 2019-07-25 2022-11-15 北京鼎持生物技术有限公司 一种全悬浮细胞培养禽流感（h9）灭活疫苗的方法
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
CN120888511B (zh) * 2025-09-28 2025-12-23 成都欧林生物科技股份有限公司 一种qmc流感毒种及其制备方法和应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988430A (en) * 1975-02-10 1976-10-26 Hoffmann-La Roche Inc. Immunoassay of antipyrine
US4315906A (en) * 1979-05-21 1982-02-16 New England Nuclear Corporation Cold insoluble globulin, its purification and use
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8703696D0 (en) 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SG46492A1 (en) 1991-03-01 1998-02-20 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
PT1075276E (pt) 1998-05-07 2008-01-22 Corixa Corp Composição adjuvante e métodos para sua utilização
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
DK1459766T3 (da) 1999-03-26 2008-10-13 Vical Inc Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
IL145702A0 (en) 1999-04-06 2002-07-25 Wisconsin Alumni Res Found Recombination influenza viruses for vaccines and gene theraphy
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DE122008000056I1 (de) 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
IL148673A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Intranasal influenza virus vaccine
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US6825036B2 (en) 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
SI1317559T1 (sl) 2000-04-28 2009-04-30 St Jude Childrens Res Hospital Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna
PT1313734E (pt) 2000-09-01 2010-02-09 Novartis Vaccines & Diagnostic Derivados aza heterocíclicos e sua utilização terapêutica
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
MXPA03008154A (es) 2001-03-09 2004-11-12 Id Biomedical Corp Quebec Novedoso adyuvante de vacuna de proteosoma-liposacarido.
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
HU228957B1 (en) * 2001-07-02 2013-07-29 Aimsco Ltd Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
BR0214407A (pt) 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
PL1742659T3 (pl) 2004-04-05 2013-08-30 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie oraz kompozycje szczepionek
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
EP2368975B1 (en) 2004-12-23 2014-09-17 MedImmune, LLC Non-tumorigenic MDCK cell line for propagating viruses
RU2435855C2 (ru) 2004-12-24 2011-12-10 Солвей Байолоджикалз Б.В. Способ продуцирования репликативной частицы вируса гриппа, композиция клеток (варианты), композиция клеточной культуры и ее применение
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
EP1917361A4 (en) 2005-06-21 2009-07-29 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING NEGATIVE SENSE RNA VIRUS IN CANINE CELLS
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CN104474543A (zh) 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗

Similar Documents

Publication Publication Date Title
JP2019011344A5 (cg-RX-API-DMAC7.html)
US7037707B2 (en) Method for generating influenza viruses and vaccines
CA2468957C (en) Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
WO2007132763A1 (ja) インフルエンザウイルスの増殖方法
JP2015119730A5 (cg-RX-API-DMAC7.html)
WO2001064846A1 (fr) Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
JP2016509864A5 (cg-RX-API-DMAC7.html)
JP2016501020A5 (cg-RX-API-DMAC7.html)
RU2708151C2 (ru) Плазмиды и способ получения вирусных частиц
Shin et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines
CN110520525B (zh) 流感工作病毒种苗与制备、增加其感染力及制备疫苗方法
CN103118704B (zh) 经修饰的病毒株及用于改善流感病毒的疫苗种子的产生的方法
CA2744354C (en) Method for production of ph stable enveloped viruses
WO2020004425A1 (ja) インフルエンザウイルスの培養方法
WO2020166524A1 (ja) 増殖方法
US20040142450A1 (en) Lung epithelial cell line for propagating viruses
CN1644686B (zh) 流感病毒哺乳动物细胞高产毒株、其重组毒株及其制备方法和应用
Mehrbod et al. Comparison of Vero and MDCK cell lines transfected with human siat7e gene for conversion to suspension culture
CN102234637A (zh) 重组甲型h1n1流感病毒灭活疫苗株(sc/pr8)的制备及应用
CN104178457A (zh) 稳定共表达人源Siat7e和ST3GalIV的MDCK细胞系及用途
JP6748067B2 (ja) インフルエンザウイルス作出用細胞
Liu et al. Screening of a high growth influenza B virus strain in Vero cells
Suzuki Recent research on influenza virus receptor and the mechanism of its host range mutation
Moreno Martin Epidemiology, genomic characterisation and evolutionary analysis of Italian H1 swine influenza viruses
JPWO2021099419A5 (cg-RX-API-DMAC7.html)